Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02551874 · ClinicalTrials.gov registry record · Phase 3

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
650
Enrollment target
20
Study locations

NCT02551874 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by AstraZeneca. The registered enrollment target is 650 participants, below the 2,743-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02551874, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
650 participants
Enrollment target
20
Study locations

Study Summary

This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to metformin with or without sulfonylurea, to subjects receiving insulin glargine, in addition to metformin with or without sulfonylurea, over a treatment period of 52 weeks.

Conditions Studied

Type 2 Diabetes Mellitus

Interventions

  • DRUG Metformin
  • DRUG Glargine insulin
  • DRUG Saxagliptin, Onglyza
  • DRUG Dapagliflozin, Farxiga

Study Locations (20)

Texas

  • Research Site - Houston
  • Research Site - Mesquite
  • Research Site - San Antonio
  • Research Site - San Antonio

Florida

  • Research Site - Miami
  • Research Site - Miami
  • Research Site - St. Petersburg

California

  • Research Site - Anaheim
  • Research Site - Los Angeles

Tennessee

  • Research Site - Bristol
  • Research Site - Kingsport

Georgia

  • Research Site - Norcross

Illinois

  • Research Site - Chicago

Kentucky

  • Research Site - Lexington

Massachusetts

  • Research Site - Quincy

Trial Details

FieldValue
Enrollment Target 650 participants
Start Date 2015-10-20
Est. Completion 2017-11-10
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02551874

The ClinicalTrials.gov registry entry for NCT02551874 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,743-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (76% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Metformin is the first listed.

NCT02551874 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, Florida, California.

Frequently Asked Questions

What is clinical trial NCT02551874 about?

NCT02551874 is a clinical study titled "A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin". This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to metformin with or without sulfonylurea, to subjects receiving insulin glargine,...

What is the current status of trial NCT02551874?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 650 participants. The study started on 2015-10-20. Estimated completion is 2017-11-10.

What conditions does trial NCT02551874 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT02551874?

The interventions under investigation include: Metformin (DRUG), Glargine insulin (DRUG), Saxagliptin, Onglyza (DRUG), Dapagliflozin, Farxiga (DRUG).

Who is sponsoring clinical trial NCT02551874?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02551874 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes Mellitus

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.